MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pum…

The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study (see graph) and the ...
MPR

Afrezza Label Update Clarifies Transition From SC to Inhaled Mealtime Insulin

Afrezza is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus.

MannKind stock rises after FDA approves updated Afrezza label

Investing.com -- MannKind Corporation (NASDAQ:MNKD) stock rose 3.5% Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing ...
InvestorsHub on MSN

MannKind shares climb after FDA clears revised Afrezza prescribing label

MannKind Corporation (NASDAQ:MNKD) shares gained 3.5% on Monday after the company said the U.S. Food and Drug Administration ...